Zobrazeno 1 - 10
of 114
pro vyhledávání: '"G.M. Kenny"'
Publikováno v:
The Prostate. 43:59-62
BACKGROUND Infusion of dendritic cells (DCs) pulsed with PSMA peptides was considered possible in hormone-refractory metastatic prostate cancer patients both with or without prior treatment with a greater number of DCs and for lesser infusions than p
Autor:
Gerald P. Murphy, M. Rogers, S.J. Simmons, Benjamin A. Tjoa, Haakon Ragde, M.J. Troychak, G.M. Kenny, Alton L. Boynton, Abdel-Aziz A. Elgamal
Publikováno v:
The Prostate. 40:125-129
BACKGROUND A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participa
Autor:
Gerald P. Murphy, S.J. Simmons, Abdel-Aziz A. Elgamal, Haakon Ragde, M.J. Troychak, Alton L. Boynton, Benjamin A. Tjoa, M. Rogers, G.M. Kenny
Publikováno v:
The Prostate. 39:291-297
BACKGROUND Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine® [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulse
Autor:
S.J. Simmons, Alton L. Boynton, Michael L Salgaller, M. Rogers, Gerald P. Murphy, Haakon Ragde, M.J. Troychak, G.M. Kenny, Benjamin A. Tjoa, Abdel-Aziz A. Elgamal
Publikováno v:
The Prostate. 39:54-59
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects adm
Autor:
G.M. Kenny, V.A. Bowes, Gerald P. Murphy, Alton L. Boynton, Abdel-Aziz A. Elgamal, J. Jarisch, M. Rogers, R.C. Ireton, Haakon Ragde, Oliver E. Cobb, M.J. Troychak, S.J. Simmons, Michael L Salgaller, Benjamin A. Tjoa
Publikováno v:
The Prostate. 38:73-78
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate canc
Autor:
Gerald P. Murphy, V.A. Bowes, Abdel-Aziz A. Elgamal, G.M. Kenny, M. Rogers, S.J. Simmons, Alton L. Boynton, R.C. Ireton, Oliver E. Cobb, Benjamin A. Tjoa, Haakon Ragde, M.J. Troychak, Michael L Salgaller
Publikováno v:
The Prostate. 36:39-44
BACKGROUND. A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and HLA-A0201-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 or -P2). Thirty-thr
Autor:
Haakon Ragde, Gerald P. Murphy, Alton L. Boynton, Mary Rogers, Joanne G. McLean, G.M. Kenny, Ben A. Tjoa, Douglas J. Loftus, Michael L. Salgaller, Patricia A. Lodge
Publikováno v:
The Prostate. 35:144-151
BACKGROUND In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS Phase II s
Autor:
Barbara Rogers, G.M. Kenny, Alkibiades K. Gregorakis, V.A. Bowes, Eric H. Holmes, Gerald P. Murphy, Alton L. Boynton, Robert T. Maguire, Haakon Ragde, M.J. Troychak, Robert J. Barren, Wil B. Nelp, Alan W. Partin
Publikováno v:
The Prostate. 33:281-285
BACKGROUND Stored serum from clinical trial cases undergoing ProstaScint® (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opp
Autor:
David C. Hoak, John Sylvester, G.M. Kenny, Kent Landin, Peter D. Grimm, William Cavanagh, Haakon Ragde, John C. Blasko
Publikováno v:
Seminars in Surgical Oncology. 13:438-443
In recent years, there has been a resurgence of interest in interstitial radiation as a cost-effective and efficient method of treating organ-confined prostate cancer. We describe our 7- and 8-year results with transperineal Iodine-125 and Palladium-
Autor:
G.M. Kenny, Haakon Ragde, Oliver E. Cobb, M.J. Troychak, Eric H. Holmes, Gerald P. Murphy, Robert J. Barren, Robert L. Wolfert, V.A. Bowes, Richard J. Kenny
Publikováno v:
The Prostate. 33:141-146
BACKGROUND Metastatic prostate cancer clinical evaluation is difficult. A revaluation of new prostate markers with regard to bone scans was performed. METHODS Serial markers, including bone alkaline phosphatase (BAP), total alkaline phosphatase (TAP)